Hisanori Muto   Teiji Kuzuya   Naoto Kawabe   Eizaburo Ohno   Kohei Funasaka   Mitsuo Nagasaka   Yoshihito Nakagawa   Ryoji Miyahara   Tomoyuki Shibata   Senju Hashimoto   Yoshiaki Katano   Yoshiki Hirooka   
Anticancer research 43(10) 4673-4682 2023年10月
BACKGROUND/AIM: The combination of atezolizumab plus bevacizumab (Atz/Bev) has become widely used as a first-line therapy for advanced hepatocellular carcinoma (HCC). However, for post-Atz/Bev therapy, evidence on the outcomes of molecular targete...